A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 Diabetes J2A-MC-GZP2: Participants With Obesity or Overweight and Type 2 Diabetes - J2A-MC-GZP2

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2051250035

Enrollment

600

Registered

2025-05-30

Start date

2025-06-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity Overweight Type 2 Diabetes

Interventions

DRUG: Orforglipron(Other Name: LY3502970) Administered orally DRUG: Placebo Administered orally (Study Arms) Experimental: Orforglipron Dose 1 Participants will receive orforglipron orally In

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Have body mass index (BMI) >=25 kilograms per square meter (kg/m2) at screening - Have type 2 diabetes - Have hemoglobin A1c (HbA1c) >=7% and <=10% at screening - Have a history of at least one unsuccessful dietary effort to lose body weight

Exclusion criteria

Exclusion criteria: - Have type 1 diabetes - Have an unstable body weight within 90 days prior to screening - Have New York Heart Association functional classification IV congestive heart failure or an acute cardiovascular condition within 90 days prior to screening - Have acute or chronic hepatitis or pancreatitis - Are taking other medications or alternative remedies to manage weight loss

Design outcomes

Primary

Measure	Time frame
Change from Baseline in Hemoglobin A1c (HbA1c) [ Time Frame: Baseline, Week 40	—

Countries

Argentina, China, Czechia, Germany, India, Japan, Mexico, Puerto Rico, United States

Contacts

Public ContactTrial Guide Call Center

Eli Lilly Japan K.K.

LTG_CallCenter@lists.lilly.com+81-120-023-812

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026